Stephens Inc. AR trimmed its position in shares of Johnson & Johnson (NYSE:JNJ) by 3.1% in the fourth quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The institutional investor owned 156,504 shares of the company’s stock after selling 4,990 shares during the period. Johnson & Johnson makes up 0.8% of Stephens Inc. AR’s portfolio, making the stock its 24th biggest position. Stephens Inc. AR’s holdings in Johnson & Johnson were worth $21,867,000 at the end of the most recent quarter.
A number of other institutional investors and hedge funds have also recently added to or reduced their stakes in the stock. Enterprise Financial Services Corp grew its holdings in Johnson & Johnson by 2.4% during the 4th quarter. Enterprise Financial Services Corp now owns 15,075 shares of the company’s stock valued at $2,106,000 after purchasing an additional 358 shares in the last quarter. Welch Investments LLC grew its holdings in Johnson & Johnson by 1.0% during the 4th quarter. Welch Investments LLC now owns 35,981 shares of the company’s stock valued at $5,027,000 after purchasing an additional 373 shares in the last quarter. YHB Investment Advisors Inc. grew its holdings in Johnson & Johnson by 0.5% during the 4th quarter. YHB Investment Advisors Inc. now owns 76,534 shares of the company’s stock valued at $10,693,000 after purchasing an additional 381 shares in the last quarter. Franklin Parlapiano Turner & Welch LLC grew its holdings in Johnson & Johnson by 1.0% during the 4th quarter. Franklin Parlapiano Turner & Welch LLC now owns 38,387 shares of the company’s stock valued at $5,363,000 after purchasing an additional 382 shares in the last quarter. Finally, Regent Investment Management LLC grew its holdings in Johnson & Johnson by 0.8% during the 4th quarter. Regent Investment Management LLC now owns 47,171 shares of the company’s stock valued at $6,591,000 after purchasing an additional 385 shares in the last quarter. 67.40% of the stock is owned by institutional investors and hedge funds.
NYSE JNJ opened at $124.24 on Friday. Johnson & Johnson has a one year low of $121.28 and a one year high of $148.32. The company has a quick ratio of 1.25, a current ratio of 1.58 and a debt-to-equity ratio of 0.47. The stock has a market capitalization of $332.28 billion, a PE ratio of 17.02, a price-to-earnings-growth ratio of 1.90 and a beta of 0.74.
Johnson & Johnson (NYSE:JNJ) last posted its quarterly earnings results on Tuesday, April 17th. The company reported $2.06 EPS for the quarter, beating the Thomson Reuters’ consensus estimate of $2.00 by $0.06. Johnson & Johnson had a net margin of 1.58% and a return on equity of 30.65%. The business had revenue of $20.01 billion during the quarter, compared to analyst estimates of $19.50 billion. During the same period in the previous year, the business posted $1.83 EPS. The company’s quarterly revenue was up 12.6% on a year-over-year basis. equities analysts forecast that Johnson & Johnson will post 8.13 EPS for the current year.
The firm also recently declared a quarterly dividend, which will be paid on Tuesday, June 12th. Stockholders of record on Tuesday, May 29th will be issued a $0.90 dividend. The ex-dividend date is Friday, May 25th. This is a positive change from Johnson & Johnson’s previous quarterly dividend of $0.84. This represents a $3.60 annualized dividend and a dividend yield of 2.90%. Johnson & Johnson’s payout ratio is 46.03%.
A number of equities research analysts recently weighed in on the stock. Credit Suisse Group set a $154.00 price target on shares of Johnson & Johnson and gave the company a “hold” rating in a report on Monday, January 22nd. BTIG Research reaffirmed a “sell” rating and set a $110.00 price target on shares of Johnson & Johnson in a report on Wednesday, January 24th. Stifel Nicolaus raised their price target on shares of Johnson & Johnson from $142.00 to $145.00 and gave the company a “hold” rating in a report on Wednesday, January 24th. Vetr raised shares of Johnson & Johnson from a “hold” rating to a “buy” rating and set a $152.28 price target for the company in a report on Tuesday, January 23rd. Finally, Citigroup decreased their price objective on shares of Johnson & Johnson from $150.00 to $146.00 and set a “neutral” rating for the company in a report on Tuesday, February 27th. Five analysts have rated the stock with a sell rating, eight have assigned a hold rating and ten have assigned a buy rating to the company’s stock. Johnson & Johnson currently has a consensus rating of “Hold” and an average target price of $142.23.
Johnson & Johnson Company Profile
Johnson & Johnson, together with its subsidiaries, researches and develops, manufactures, and sells various products in the health care field worldwide. Its Consumer segment offers baby care products under the JOHNSON'S brand; oral care products under the LISTERINE brand; beauty products under the AVEENO, CLEAN & CLEAR, DABAO, JOHNSON'S Adult, LE PETITE MARSEILLAIS, NEUTROGENA, RoC, and OGX brands; over-the-counter medicines, including acetaminophen products under the TYLENOL brand; cold, flu, and allergy products under the SUDAFED brand; allergy products under the BENADRYL and ZYRTEC brands; ibuprofen products under the MOTRIN IB brand; and acid reflux products under the PEPCID brand.
Want to see what other hedge funds are holding JNJ? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Johnson & Johnson (NYSE:JNJ).
Receive News & Ratings for Johnson & Johnson Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Johnson & Johnson and related companies with MarketBeat.com's FREE daily email newsletter.